Drug Profile
Research programme: antibody-based cancer therapeutics and diagnostics - Neoantigenics/Pfizer
Latest Information Update: 28 Mar 2018
Price :
$50
*
At a glance
- Originator Neoantigenics
- Class Antibodies; Antibody diagnostics; Diagnostic agents
- Mechanism of Action Membrane protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Mar 2018 No recent reports of development identified for research development in Cancer in USA
- 28 Mar 2018 No recent reports of development identified for research development in Cancer(Diagnosis) in USA
- 29 Jan 2014 Early research in Cancer (Diagnosis) in USA (unspecified route)